Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

BRAIN Biotech AG ( ETR:BNN ) shareholders will doubtless be very grateful to see the share price up 80% in the ...

By focusing on data quality, domain-specific knowledge, and the synergy between humans and machine learning, AI and biotech ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last ...

Scott Rapoport earned his PhD in marine biology from Scripps Institution of Oceanography at UC San Diego in 2003. Drawn to ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced ...

IPOs at three biotechs last week tempted insiders to make huge share purchases. This spilled over into buying at a couple of ...

Andres Maldonado of H.C. Wainwright reiterated a Buy rating for Corbus with an $80 price target. Oppenheimer also maintained ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The results of the study show that treatment with Carragelose eye drops for four weeks significantly improves dry eye-related symptoms by 54%. Next to excellent tolerability, patients also reported a ...